Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines

International Journal of Molecular Medicine

Volumn 24, Issue 4, 2009, Pages 549-556

  Farnebo, Lovisa ^a   Jedlinski, Adam ^a   Ansell, Anna ^a   Vainikka, Linda ^a   Thunell, Lena K ^b   Grénman, Reidar ^c   Johansson, Ann Charlotte ^a,d   Roberg, Karin ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bax; Bcl 2; DNA repair genes; Epidermal growth factor receptor; Heat shock protein 70

Indexed keywords

CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; HEAT SHOCK PROTEIN 70; PROTEIN BAX; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; SURVIVIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GROWTH REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELLS, CULTURED; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TUMOR SUPPRESSOR PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 70350786144     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000264     Document Type: Article

References (32)

1. Shah JP and Lydiatt W: Treatment of cancer of the head and neck. CA Cancer J Clin 45: 352-368, 1995.
2. Fried4. Bauer JA, Kumar B, Cordell KG, et al: Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 69: S106-S108, 2007.
3. Bakkenist CJ and Kastan MB: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506, 2003.
4. Bauer JA, Kumar B, Cordell KG, et al: Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 69: S106-S108, 2007.
5. Guo B, Cao S, Toth K, Azrak RG and Rustum YM: Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 6: 718-724, 2000.
6. Yu J, Yue W, Wu B and Zhang L: PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12: 2928-2936, 2006.
7. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
8. Loeffler-Ragg J, Schwentner I, Sprinzl GM and Zwierzina H: EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 17: 1517-1531, 2008.
9. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
10. Milas L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11: 290-299, 2001.
11. Koki AT, Leahy KM and Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 8: 1623-1638, 1999.
12. Lo Muzio L, Pannone G, Staibano S, et al: Survivin expression in oral squamous cell carcinoma. Br J Cancer 89: 2244-2248, 2003.
13. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006.
14. Zhan Q, Bae I, Kastan MB and Fornace AJ Jr: The p53- dependent gamma-ray response of GADD45. Cancer Res 54: 2755-2760, 1994.
15. Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
16. Ansell A, Farnebo L, Grenman R, Roberg K and Thunell LK: Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 45: 23-29, 2009.
17. Farnebo L, Jerhammar F, Vainikka L, Grenman R, Norberg- Spaak L and Roberg K: Number of negative points: a novel method for predicting radiosensitivity in head and neck tumor cell lines. Oncol Rep 20: 453-461, 2008.
18. Nilsson JA, Hedberg JJ, Vondracek M, et al: Alcohol dehydrogenase 3 transcription associates with proliferation of human oral keratinocytes. Cell Mol Life Sci 61: 610-617, 2004.
19. Pekkola-Heino K, Jaakkola M, Kulmala J and Grenman R: Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol 121: 452-456, 1995.
20. Grenman R, Burk D, Virolainen E, et al: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
21. Fertil B, Deschavanne PJ, Gueulette J, Possoz A, Wambersie A and Malaise EP: In vitro radiosensitivity of six human cell lines. II. Relation to the RBE of 50-MeV neutrons. Radiat Res 90: 526- 537, 1982.
22. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
23. Burtness B: Cetuximab and cisplatin for chemotherapyrefractory squamous cell cancer of the head and neck. J Clin Oncol 23: 5440-5442, 2005.
24. Vargas-Roig LM, Gago FE, Tello O, Aznar JC and Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79: 468-475, 1998.
25. Kang SY, Han JH, Lee KJ, et al: Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 13: 4146-4153, 2007.
26. Tsuji T, Noguchi M, Kido Y, et al: Predictive assay of neoadjuvant chemotherapy in management of oral cancer. Int J Oral Maxillofac Surg 36: 15-19, 2007.
27. Schneider-Stock R, Mawrin C, Motsch C, et al: Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 164: 1233-1241, 2004.
28. Bond GL, Hu W and Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481-5484, 2005.
29. Hoffmann TK, Sonkoly E, Hauser U, et al: Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44: 1100-1109, 2008.
30. Quintela-Fandino M, Hitt R, Medina PP, et al: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24: 4333-4339, 2006.
31. Font A, Salazar R, Maurel J, et al: Cisplatin plus weekly CPT- 11/ docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol 62: 1075-1083, 2008.
32. Erjala K, Pulkkinen J, Kulmala J, Alanen K and Grenman R: Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 22: 3135-3142, 2002.